---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-314167"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:38:41.775888+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics increases wet AMD trial enrollment to 480 patients for global regulatory submissions

## Summary
- Target enrollment for 4FRONT-1 and 4FRONT-2 Phase 3 trials raised from 400 to 480 patients each.
- Amendments aim for ~90% power with ~4-letter noninferiority margin for non-FDA agencies (e.g., PMDA, EMA).
- No impact on guided enrollment completion or financial runway into H2 2028; 4FRONT-1 topline expected H1 2027.
- Asia-Pacific regulatory submissions supported by Otsuka partnership, leveraging global commercial opportunity.

## SEC filing metadata
- accession: 0001193125-25-314167
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/0001193125-25-314167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-314167
- JSON: https://secwatch.observer/filing/0001193125-25-314167.json
- Plain text: https://secwatch.observer/filing/0001193125-25-314167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.